About the Company
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MNK News
Mallinckrodt gets grant for filter apparatus for liquid removal from gas
Discover Mallinckrodt Plc's innovative patent for a filter apparatus removing liquid from gas efficiently. Learn about the unique features and benefits of this groundbreaking technology.
Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Mallinckrodt plc: Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award
In recognition of 30 years of Extracorporeal Photopheresis Use for Chronic Graft vs. Host Disease (cGvHD), this year's grant is to be dedicated to research in cGvHD -- -- Investigators ...
Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance
2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported its financial results for the fourth quarter and fiscal year ...
Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award
Mallinckrodt plc, a global specialty pharmacy company, today announced that submissions for its 2024 Extracorporeal Immunomodulation Award (EIA) will open on 13 April 2024 during the 50th Annual ...
Mallinckrodt plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance
View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-plc-reports-fourth-quarter-and-fiscal-year-2023-financial-results ...
Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award
2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmacy company, today announced that submissions for its 2024 Extracorporeal Immunomodulation Award (EIA) will open on 13 April 2024 ...
Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award
Part of Mallinckrodt's ongoing commitment to the science of immunomodulation through ECP is to recognize individuals and institutions whose research contributes to the advancement of knowledge in ...
Loading the latest forecasts...